Achievement of Phase 1 Dose Escalation Criteria in AbbVie Partnership on CX-2029, a CD71-Directed Probody® Drug Conjugate, Triggers $40 Million Payment to CytomX Clinical Studies for CX-2009 and CX-072 impacted by Global COVID-19 Pandemic, Prompting Pipeline Reprioritization Conference Call Today,

SOUTH SAN FRANCISCO, Calif. , March 25, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody ® therapeutic technology platform, today

       - Collaboration to Utilize CytomX’s Novel Probody ® Technology Platform for CD3 Bispecific Targets -        - CytomX to Receive $80 Million Upfront Payment and        Ability to Exercise Option for U.S. Co-Commercialization Rights - SOUTH SAN FRANCISCO, Calif.

SOUTH SAN FRANCISCO, Calif. , March 23, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today

SOUTH SAN FRANCISCO, Calif. , March 16, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today

Company to Host a Conference Call Today, February 27, 2020, at 5:00 p.m. ET / 2:00 p.m. PT SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of

SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today

Expansion Phase to Evaluate CTLA-4-Directed Probody ®  Therapeutic in Combination with Opdivo ® in Metastatic Melanoma  Bristol-Myers Squibb also Advances BMS-986288 into a Separate Phase 1/2a Clinical Trial SOUTH SAN FRANCISCO, Calif. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc.

-Teleconference Scheduled for February 27, 2020, at 5:00 p.m. ET- SOUTH SAN FRANCISCO, Calif. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics

SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody ® therapeutic technology platform, today